How Which Wich Is Innovating Through Staffing Challenges

 

Changing the future of restaurant staffing is a new digital ordering tool. According to QSR, a disappointing restaurant experience during the pandemic prompted Which Wich CEO Jeff Sinelli to introduce Yellow Lab technology, an in-store digital ordering service that allows guests to order from a kiosk rather than at the counter. YellowLab’s remote ordering kiosks offer many benefits, including the ability to operate them simultaneously from multiple locations within the restaurant, streamlining the staff’s workday.

Barbara Castiglia, Executive Editor, of Modern Restaurant Management gives her take on how the introduction of this digital ordering technology will assist restaurants as they deal with current staffing challenges and more.

 

Barbara’s Thoughts:

“Hi, this is Barbara Castiglia of Modern Restaurant Management. The words remote and restaurant work usually don’t go together, particularly when it involves sandwiches. But an interesting innovation is coming about that one sandwich chain is using. What they’re referring to is a virtual cashier.

And this is the chain which, and what they’re doing is using ordering kiosks, but they have a remote video calling cashiers. So the customer gets to the interface. With an actual person. And this is really interesting, twofold. It’s really many folds actually. It’s really saying what we can do with technology and restaurants and this actual technology that allows this interface, to work.

And what it means for restaurants, where we’re facing such big staffing challenges is, they can have a person remotely be that interface for the brand and somebody else is focused on making that really great sandwich. So it works really well together.”

Follow us on social media for the latest updates in B2B!

Image

Latest

cancer Immunity cycle
Advanced In Vitro Technologies to Investigate Therapeutic Impact on the Cancer Immunity Cycle
April 19, 2025

As immunotherapy revolutionizes cancer treatment, the need for physiologically relevant preclinical models becomes more urgent than ever. Despite the success of immune checkpoint inhibitors, a large majority of patients fail to achieve long-lasting responses, prompting researchers to explore more complex and predictive assays. The cancer immunity cycle, first described in 2013, remains a central framework…

Read More
resistance
Inside Oncology Drug Development: Overcoming Resistance with Science
April 19, 2025

In the last two decades, oncology has undergone a transformation with over 300 new cancer therapies approved by the FDA—many offering novel mechanisms of action. Despite these innovations, resistance to treatment remains a critical challenge, with cancer cells evolving or adapting to evade even the most advanced therapeutics. This issue is particularly pressing given that…

Read More
organoids
Growing the Future of Cancer Research: Inside the Promise of Organoids
April 19, 2025

In an era where precision and predictability define the future of oncology, organoid technology is emerging as a transformative tool in drug discovery. These miniature, lab-grown 3D tissues mirror real human biology more closely than traditional 2D models or even animal systems, offering researchers the potential to predict patient-specific drug responses. As organoids become more…

Read More
Immuno-Oncology
Shaping the Future of Cancer Care Through Immuno-Oncology
April 19, 2025

In the ever-evolving world of cancer treatment, immuno-oncology (IO) continues to stand at the forefront of innovation. With recent FDA approvals for TIL therapies and bispecific antibodies, and new developments in CAR-T technologies, the field is rapidly expanding into combination-based strategies that integrate with standard care. Researchers are also exploring how to overcome challenges posed…

Read More